Clinical Trials

60 enrolled

Triple Negative Breast Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

31 enrolled

Triple Negative Breast Neoplasms

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Recruiting

70 enrolled

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07178730 2026-05-06

ADAPT-TN-IV

765 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05143229 2026-05-01

ASSET

18 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07134556 2026-05-01

ADJUNCT

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05633654 2026-04-30

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Triple Negative Breast Neoplasms

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04595565 2026-04-22

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

145 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

364 enrolled

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

75 enrolled

Breast Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

80 enrolled

Triple Negative Breast Neoplasms

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT07367178 2026-01-28

SATROPIN

30 enrolled

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Phase 2 Enrolling by invitation

Breast Neoplasms

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

60 enrolled

Advanced Breast Cancer

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Breast Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

24 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06612203 2025-12-05

WIN-B

76 enrolled

Advanced Breast Cancer

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT07251868 2025-11-26

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Recruiting

100 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Triple Negative Breast Neoplasms

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06827613 2025-09-24

START-002

50 enrolled

Triple Negative Locally Advanced Non-resectable Breast Cancer

NCT05382286 2025-09-18

ASCENT-04

443 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06504719 2025-09-15

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Completed

312 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

40 enrolled

Breast Cancer Metastatic

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

20 enrolled

Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

20 enrolled